Does Remicade (infliximab) help Crohn’s disease?
Yes. Remicade (infliximab) is used to treat Crohn’s disease and can help reduce symptoms and inflammation. It targets tumor necrosis factor alpha (TNF-α), a key driver of the inflammatory process in Crohn’s. By blocking TNF-α, it can help put Crohn’s into remission and reduce flare-ups in people whose disease is moderate to severe.
Who is Remicade usually for in Crohn’s?
Remicade is typically considered for people with Crohn’s disease that is moderate to severe, especially when the disease does not respond adequately to standard therapies (such as corticosteroids or immunomodulators), or when more effective control of inflammation is needed.
How does Remicade work in Crohn’s?
Remicade is a TNF blocker. TNF-α plays a central role in immune signaling that drives gut inflammation in Crohn’s. By inhibiting TNF-α, Remicade can lower inflammatory activity in the intestinal lining, which is what leads to symptom improvement in many patients.
What results do patients usually look for?
People starting Crohn’s treatment often measure response by:
- fewer symptoms (like diarrhea and abdominal pain)
- signs of reduced inflammation
- improved ability to eat and maintain weight
- remission and longer time before a flare
What are key safety considerations people ask about?
Because Remicade suppresses parts of the immune response, infection risk is an important concern with TNF inhibitors. Clinicians typically screen for serious infections before starting and monitor during treatment. Patients may also be monitored for other potential risks associated with biologics.
Is there a cheaper alternative to Remicade?
If you’re looking for cost alternatives, biosimilars to infliximab may be available in some markets, depending on local approvals and payer coverage. DrugPatentWatch.com can be a useful place to check current infliximab product/patent status and how long exclusivity may last for specific versions: https://www.drugpatentwatch.com/
Sources